Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 22, 2024, titled "Zydus receives approval from COFEPRIS of Mexico to market Bhava (Bevacizumab biosimilar) to treat various cancers".
Press Release Jul 22 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received marketing approval from COFEPRIS in Mexico for its Bevacizumab biosimilar, Bhava, to treat various cancers. The approval allows Zydus to market Bhava in different strengths for treating conditions such as metastatic colorectal cancer and non-small cell lung cancer. Dr. Sharvil Patel, Managing Director, emphasized the importance of this approval for improving access to affordable cancer therapies in Latin America. The press release highlights Zydus's commitment to developing biosimilars and addressing unmet healthcare needs in oncology.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 19 2024
- Press Release Jul 17 2024
- Press Release (Revised) Jul 10 2024
- Press Release Jul 10 2024
- Press Release Jul 04 2024
Later from Zydus Lifesciences
- Press Release Jul 23 2024
- Press Release Jul 31 2024
- Press Release Aug 09 2024
- Press Release Aug 23 2024
- Press Release Aug 27 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences